HK1216502A1 - 用於癌症治療的反式-克羅米芬 - Google Patents

用於癌症治療的反式-克羅米芬

Info

Publication number
HK1216502A1
HK1216502A1 HK16104449.1A HK16104449A HK1216502A1 HK 1216502 A1 HK1216502 A1 HK 1216502A1 HK 16104449 A HK16104449 A HK 16104449A HK 1216502 A1 HK1216502 A1 HK 1216502A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
trans clomiphene
clomiphene
trans
cancer
Prior art date
Application number
HK16104449.1A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Kuang Hsu
Greg Fontenot
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of HK1216502A1 publication Critical patent/HK1216502A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
HK16104449.1A 2012-11-02 2016-04-19 用於癌症治療的反式-克羅米芬 HK1216502A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722013P 2012-11-02 2012-11-02
PCT/US2013/066141 WO2014070523A1 (en) 2012-11-02 2013-10-22 Trans-clomiphene for use in cancer therapy

Publications (1)

Publication Number Publication Date
HK1216502A1 true HK1216502A1 (zh) 2016-11-18

Family

ID=50627954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104449.1A HK1216502A1 (zh) 2012-11-02 2016-04-19 用於癌症治療的反式-克羅米芬

Country Status (10)

Country Link
US (1) US9687458B2 (zh)
EP (1) EP2914294A1 (zh)
JP (3) JP2015535283A (zh)
CN (1) CN104994877A (zh)
AU (1) AU2013338311A1 (zh)
CA (1) CA2889770A1 (zh)
HK (1) HK1216502A1 (zh)
IL (1) IL238453A0 (zh)
MX (1) MX2015005160A (zh)
WO (1) WO2014070523A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022325A1 (en) * 2014-08-05 2016-02-11 The Penn State Research Foundation Novel triarylethylene compounds and methods using same
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
JP2018002619A (ja) * 2016-06-29 2018-01-11 国立大学法人 東京大学 オートファジー阻害剤
EP3515424A4 (en) * 2016-09-26 2020-05-06 Repros Therapeutics Inc. ANTI-ESTROGEN AND / OR AROMATASE INHIBITORS FOR USE IN THE TREATMENT OF ADIPOSITAS AND RELATED SYMPTOMS
CN108420806A (zh) * 2017-02-15 2018-08-21 武汉华杰世纪生物医药有限公司 具有靶向性的抗肿瘤药物
WO2019236209A2 (en) * 2018-04-27 2019-12-12 Jin Byung Ju Methods for high-content drug screening

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
WO1994006762A1 (en) 1992-09-15 1994-03-31 Merrell Dow Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU2638795A (en) 1994-06-17 1996-01-15 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
EP0844870B1 (en) 1995-08-17 2001-11-21 Csir Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
NZ510201A (en) 1998-07-30 2002-10-25 Stoller Ets Treatment of plants with salicylic acid and organic amines
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL352250A1 (en) 1999-06-11 2003-08-11 Watson Pharmaceuticals Administration of non-oral androgenic steroids to women
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
NZ534348A (en) 2000-01-28 2006-06-30 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CA2409647C (en) 2000-05-26 2012-07-03 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CA2416976C (en) 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
CN1954807A (zh) 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2002330031B2 (en) 2001-09-21 2007-07-05 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
BRPI0606528A8 (pt) 2005-02-04 2018-03-13 Repros Therapeutics Inc composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
RU2413508C2 (ru) * 2005-03-22 2011-03-10 Репрос Терапьютикс Инк. Режимы дозирования транс-кломифена
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
JP2009503096A (ja) 2005-08-05 2009-01-29 リプロス セラピューティクス インコーポレイテッド クロミフェンを用いる女性不妊症を処置するための方法および組成物
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
ES2381175T3 (es) 2007-06-26 2012-05-23 Media Patents, S. L. Dispositivo para gestionar grupos multidifusión
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2826475B1 (en) 2007-10-16 2019-03-20 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第2型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) * 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
US20150031656A1 (en) 2012-02-29 2015-01-29 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
SG10201704820SA (en) 2012-08-21 2017-07-28 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技(苏州)有限公司 一种克罗米芬的合成方法

Also Published As

Publication number Publication date
US20150283099A1 (en) 2015-10-08
JP2021046448A (ja) 2021-03-25
MX2015005160A (es) 2015-07-17
IL238453A0 (en) 2015-06-30
WO2014070523A1 (en) 2014-05-08
JP2018123168A (ja) 2018-08-09
CN104994877A (zh) 2015-10-21
US9687458B2 (en) 2017-06-27
EP2914294A1 (en) 2015-09-09
CA2889770A1 (en) 2014-05-08
AU2013338311A1 (en) 2015-05-14
JP2015535283A (ja) 2015-12-10

Similar Documents

Publication Publication Date Title
IL267242B (en) Cancer treatment
HK1213444A1 (zh) 癌症的治療
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1252579A1 (zh) 作為用於治療乳腺癌的基於硼的4-羥基他莫昔芬和因多昔芬前藥
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2807180A4 (en) PEPTIDE AGENTS USED IN ANTICANCER THERAPY
HK1216502A1 (zh) 用於癌症治療的反式-克羅米芬
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
HK1210023A1 (zh) 癌症治療
GB201207305D0 (en) Therapy
SG11201502317VA (en) Telomerase inhibitors for use in therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
AU2012900259A0 (en) Agents for use in cancer therapy
IL239231A0 (en) Combined cancer treatment
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201214454D0 (en) Therapeutic treatments
GB201214456D0 (en) Therapeutic treatments